
ME
Healthcare · Diagnostics & Research · $13.3M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 29, 2025 | Time not confirmed | — | -2.01 | — |
| Nov 12, 2024 | Time not confirmed | — | -2.32 | — |
| Aug 8, 2024 | After the close | -0.22 | -0.12 | +45.5% |
| May 24, 2024 | After the close | -0.15 | -0.11 | +26.7% |
| Feb 7, 2024 | After the close | -0.14 | -0.16 | -14.3% |
| Nov 8, 2023 | After the close | -0.14 | -0.16 | -14.3% |
| Aug 8, 2023 | After the close | -0.15 | -0.23 | -53.3% |
| May 25, 2023 | After the close | -0.16 | -0.14 | +12.5% |
| Feb 8, 2023 | After the close | -0.19 | -0.02 | +89.5% |
| Nov 7, 2022 | After the close | -0.17 | -0.15 | +11.8% |
| Aug 8, 2022 | After the close | -0.16 | -0.20 | -25.0% |
| May 26, 2022 | After the close | -0.13 | -0.13 | 0.0% |
| Feb 10, 2022 | After the close | -0.16 | -0.21 |
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins,…
| -31.3% |
| Nov 10, 2021 | After the close | -0.11 | -0.11 | 0.0% |
| Aug 13, 2021 | Before the open | -0.57 | -0.25 | +55.9% |
| Jun 3, 2021 | After the close | — | -0.57 | — |
| Mar 24, 2021 | Time not confirmed | — | -1.36 | — |
| Nov 16, 2020 | Time not confirmed | — | 0.00 | — |
| Sep 16, 2020 | Time not confirmed | — | 0.00 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.38 | — |